Immune Checkpoint Inhibitors in the Treatment of Renal Cancer: Current State and Future Perspective

Systemic treatment of renal cancer (RCC) has undergone remarkable changes over the past 20 years with the introduction of immunotherapeutic agents targeting programmed cell death (PD-1)/programmed death-ligand 1 (PD-L1) axis, as a single-agent or combined with anti-CTLA-4 monoclonal antibodies (MoAb...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Int J Mol Sci
Hauptverfasser: Lavacchi, Daniele, Pellegrini, Elisa, Palmieri, Valeria Emma, Doni, Laura, Mela, Marinella Micol, Di Maida, Fabrizio, Amedei, Amedeo, Pillozzi, Serena, Carini, Marco, Antonuzzo, Lorenzo
Format: Artigo
Sprache:Inglês
Veröffentlicht: MDPI 2020
Schlagworte:
Review
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7369721/
https://ncbi.nlm.nih.gov/pubmed/32630154
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms21134691
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge